Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTheralase Technologies Inc.

Theralase Technologies Inc.

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.18 CAD -0.01 ( 7.69%)
Last update at 2026-11-03T20:41:00Z
VOLUME
40902
Market Cap
90.16M

Momentum Score

…

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.18
Low
0.20
High
52 Week Price Range
0.15
Low
0.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Theralase Technologies develops photodynamic and photothermal therapeutics and medical devices using proprietary photosensitizers and laser systems for oncology, antimicrobial and wound-care applications. Long-term growth drivers include clinical trial progress, adoption of non-invasive phototherapies, and protection from intellectual property and potential partnerships; investors may find the company attractive for exposure to emerging medical-device and phototherapy technologies with possible clinical utility.
Key risks include early-stage commercialisation with limited revenue, substantial regulatory and clinical execution uncertainty, ongoing financing needs, and thin market liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.20
Dividend Yield
-
Revenue TTM
1.00M
Revenue Per Share
0.00
Gross Profit TTM
0.55M
Debt / Equity
0.20
ROE
-269.41%
Net Debt
0.34M
ROCE
-189.67%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.26M -4.57M -5.24M -4.41M -5.60M
Net income -4.26M -4.57M -5.25M -4.42M -5.61M
Selling general administrative 2.05M 2.03M 1.44M 1.75M 2.02M
Selling and marketing expenses - 0.10M 0.09M 0.10M 0.45M
Gross profit 0.55M 0.31M 0.63M 0.31M 0.27M
Reconciled depreciation 0.27M 0.29M 0.31M 0.28M 0.27M
Ebit - -4.59M -5.20M -4.52M -5.59M
Ebitda - -4.31M -4.89M -4.24M -5.32M
Depreciation and amortization - 0.29M 0.31M 0.28M 0.27M
Operating income -4.29M -4.59M -5.20M -4.52M -5.59M
Other operating expenses - 5.66M 6.37M 5.32M 6.63M
Interest expense 0.02M 0.03M 0.02M 0.01M 0.01M
Interest income 0.07M 0.05M 0.03M 0.02M 0.10M
Net interest income 0.04M 0.02M 0.01M 0.02M 0.09M
Income tax expense - -0.00M 0.01M 0.01M 0.01M
Total revenue 1.03M 1.07M 1.14M 0.78M 0.93M
Total operating expenses 5.32M 4.90M 5.86M 4.85M 5.97M
Cost of revenue 0.48M 0.77M 0.51M 0.47M 0.66M
Total other income expense net -0.01M 0.02M -0.03M 0.11M -0.01M
Net income from continuing ops -4.26M -4.57M -5.24M -4.41M -5.60M
Net income applicable to common shares - - -5.24M -4.41M -5.60M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 3.25M 3.28M 4.16M 5.94M 10.02M
Other current assets 0.06M 0.20M - 0.44M 0.10M
Total liab 1.18M 1.37M 1.07M 0.87M 0.86M
Total stockholder equity 2.07M 1.91M 3.09M 5.07M 9.16M
Other current liab - 0.30M 0.59M - 0.76M
Common stock - 46.44M 44.53M 42.12M 42.12M
Capital stock 48.92M 46.44M 44.53M 42.12M 42.12M
Retained earnings -67.50M -63.24M -58.45M -53.09M -48.51M
Other assets - - 0.55M 0.08M 0.06M
Cash 0.27M 0.04M 1.51M 3.69M 7.88M
Total current liabilities 0.99M 1.08M 0.68M 0.87M 0.82M
Net debt - 0.34M - - -
Short term debt - 0.09M - - -
Short long term debt total - 0.39M - - -
Other stockholder equity - 12.49M 5.64M 5.10M 5.30M
Property plant equipment - - 1.11M 0.87M 1.04M
Total current assets 1.58M 1.50M 2.50M 5.00M 8.92M
Net tangible assets - - 3.09M 5.07M 9.16M
Net receivables 0.17M 0.60M 0.44M 0.30M 0.49M
Inventory 0.55M 0.66M 0.49M 0.57M 0.45M
Accounts payable 0.36M 0.68M 0.33M 0.50M 0.41M
Accumulated other comprehensive income - 6.22M - - -
Non currrent assets other -0.00M 0.92M - -0.00M -
Non current assets total 1.66M 1.78M 1.66M 0.95M 1.11M
Capital lease obligations 0.29M 0.39M 0.47M 0.04M 0.09M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.02M -0.04M -0.07M -0.10M -0.16M
Change to liabilities - - -0.27M 0.07M -0.71M
Total cashflows from investing activities - - -0.07M -0.10M -0.16M
Net borrowings -0.12M - -0.05M -0.06M -0.05M
Total cash from financing activities 3.57M 2.65M 3.02M -0.06M -0.06M
Change to operating activities - - -0.23M -0.38M 0.05M
Net income -4.26M -4.57M -5.24M -4.41M -5.60M
Change in cash 0.22M -1.46M -2.18M -4.19M -4.67M
Begin period cash flow 0.04M 1.51M 3.69M 7.88M 12.55M
End period cash flow 0.27M 0.04M 1.51M 3.69M 7.88M
Total cash from operating activities -3.33M -4.07M -5.13M -4.03M -4.45M
Issuance of capital stock 3.69M 2.76M 2.72M 0.00M 1.60M
Depreciation 0.27M 0.29M 0.31M 0.28M 0.27M
Change to inventory 0.11M -0.17M 0.08M -0.11M 0.27M
Change to account receivables -0.02M -0.03M -0.03M 0.23M 0.39M
Other cashflows from financing activities - 2.76M 0.34M -0.00M -0.01M
Change to netincome - - 0.24M 0.34M 0.93M
Capital expenditures 0.02M 0.04M 0.07M 0.10M 0.16M
Change in working capital 0.10M -0.44M -0.45M -0.24M -0.05M
Stock based compensation 0.52M 0.62M 0.19M 0.32M 0.91M
Other non cash items 0.02M 1.03M 0.05M 0.01M 0.01M
Free cash flow -3.35M -4.11M -5.20M -4.13M -4.61M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TLT
Theralase Technologies Inc.		 -0.01
7.69%		 0.18 - - 90.07 82.51 90.31 -12.06
CNVI
Conavi Medical Corp.		 -0.01
4.35%		 0.11 - - 66.65 - 95.30 -
PINK
Perimeter Medical Imaging AI Inc		 0.01
9.68%		 0.17 4.13 - 18.78 11.34 20.22 -2.55
CHER
Cheelcare Inc.		 -
-%		 1.22 - - 20.92 106.42 21.26 -
ASG
Aurora Spine Corp		 0.01
15.00%		 0.12 - - 1.19 4.07 1.02 202.96

Profile*

Theralase Technologies Inc.

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

41 Hollinger Road, Toronto, ON, Canada, M4B 3G4

416 699 5273

https://www.theralase.com

Name Title Year Born
Dr. Arkady Mandel DSc., M.D., Ph.D. Interim CEO, Chief Scientific Officer & Director NA
Ms. Kristina Hachey CPA CFO & Director NA
Mr. David M. Groves B.A Pres of World Trade Division NA
Mr. Roger John Dumoulin-White Director of Bus. Devel. NA
Lori Leach Marketing & Media Relations Consultant NA
Mr. Vaughn Wyant Marketing & Media Relations Consultant NA
Dr. Terry Ruch DVM Equine Medical Consultant NA
Mr. Roger John Dumoulin-White B.Sc., P.Eng. President, CEO & Director NA
Dr. Arkady Mandel DSc., M.D., Ph.D. Chief Scientific Officer & Director NA
Mr. David M. Groves B.A President of World Trade Division NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…